PDF herunterladen
Semin Neurol 2016; 36(06): 615-624
DOI: 10.1055/s-0036-1592106
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-Barré Syndrome

Alexis A. Lizarraga
1   Department of Neurology, University of Miami School of Medicine, Miami, Florida
,
Karlo J. Lizarraga
1   Department of Neurology, University of Miami School of Medicine, Miami, Florida
,
Michael Benatar
1   Department of Neurology, University of Miami School of Medicine, Miami, Florida
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. Dezember 2016 (online)

    Lizenzen und Reprints

Abstract

After prompt diagnosis, severe myasthenia gravis and Guillain-Barré syndrome (GBS) usually require management in the intensive care unit. In the myasthenic patient, recognition of precipitating factors is paramount, and frequent monitoring of bulbar, upper airway, and/or respiratory muscle strength is needed to identify impending myasthenic crisis. Noninvasive ventilation can be attempted prior to intubation and mechanical ventilation in the setting of respiratory failure. Cholinesterase inhibitors should be discontinued, but resumed prior to extubation, and steroid dosage could be increased once the airway is secured. In GBS, hemodynamic and respiratory monitoring are essential; however, respiratory failure can develop rapidly and intubation with mechanical ventilation is often required and can be prolonged. Guillain-Barré syndrome can also be complicated by dysautonomia necessitating specific therapies. Prompt recognition and initiation of immunotherapy including intravenous immunoglobulin or plasmapheresis, together with supportive care including treatment of underlying infections and physical therapy, can improve outcomes in both myasthenic crisis and GBS.

Keywords

Guillain-Barré syndrome - acute inflammatory demyelinating polyradiculo-neuropathy - myasthenia gravis - myasthenic crisis - neurocritical care
 

  • References

  • 1 Sanders DB, Wolfe GI, Benatar M , et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016;
    PubMedSuche in Google Scholar
  • 2 Keesey JC. “Crisis” in myasthenia gravis: an historical perspective. Muscle Nerve 2002; 26 (1) 1-3
    CrossrefPubMedSuche in Google Scholar
  • 3 Bedlack RS, Sanders DB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis 2002; 4 (1) 40-42
    CrossrefPubMedSuche in Google Scholar
  • 4 Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl 2014; 129 (198) 26-31
    CrossrefPubMedSuche in Google Scholar
  • 5 McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 2010; 34 (3) 171-183
    CrossrefPubMedSuche in Google Scholar
  • 6 Thomas CE, Mayer SA, Gungor Y , et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48 (5) 1253-1260
    CrossrefPubMedSuche in Google Scholar
  • 7 Ropper AH, Gress DR, Diringer MN, Green DM, Mayer SA, Bleck TP. Treatment of the Critically Ill Patient With Myasthenia Gravis. Neurological and Neurosurgical Intensive Care. 4th ed. Philadelphia, PA: Lipincott Williams & Wilkins; 2004: 299-311
    Suche in Google Scholar
  • 8 Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72 (18) 1548-1554
    CrossrefPubMedSuche in Google Scholar
  • 9 Ramos-Fransi A, Rojas-García R, Segovia S , et al; Myasthenia NMD-ES Study Group. Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 2015; 22 (7) 1056-1061
    CrossrefPubMedSuche in Google Scholar
  • 10 Rabinstein A. Acute neuromuscular respiratory failure. In: Continuum: critical care, acute neuromuscular respiratory failure. 2015; 21 (5) 1324-1345
    PubMedSuche in Google Scholar
  • 11 Sakaguchi H, Yamashita S, Hirano T , et al. Myasthenic crisis patients who require intensive care unit management. Muscle Nerve 2012; 46 (3) 440-442
    CrossrefPubMedSuche in Google Scholar
  • 12 Kalita J, Kohat AK, Misra UK. Predictors of outcome of myasthenic crisis. Neurol Sci 2014; 35 (7) 1109-1114
    CrossrefPubMedSuche in Google Scholar
  • 13 Soleimani A, Moayyeri A, Akhondzadeh S, Sadatsafavi M, Tavakoli Shalmani H, Soltanzadeh A. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. BMC Neurol 2004; 4: 12
    CrossrefPubMedSuche in Google Scholar
  • 14 Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44 (1) 36-40
    CrossrefPubMedSuche in Google Scholar
  • 15 Evoli A, Tonali PA, Padua L , et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126 (Pt 10): 2304-2311
    CrossrefPubMedSuche in Google Scholar
  • 16 Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60 (12) 1978-1980
    CrossrefPubMedSuche in Google Scholar
  • 17 Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505: 472-499
    CrossrefPubMedSuche in Google Scholar
  • 18 Benatar M. Pearls: myasthenia. Semin Neurol 2010; 30 (1) 35-37
    Thieme ConnectPubMedSuche in Google Scholar
  • 19 Rieder P, Louis M, Jolliet P, Chevrolet JC. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995; 21 (8) 663-668
    CrossrefPubMedSuche in Google Scholar
  • 20 Agarwal R, Reddy C, Gupta D. Noninvasive ventilation in acute neuromuscular respiratory failure due to myasthenic crisis: case report and review of literature. Emerg Med J 2006; 23 (1) e6
    CrossrefPubMedSuche in Google Scholar
  • 21 Rabinstein A, Wijdicks EFM. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation. Neurology 2002; 59 (10) 1647-1649
    CrossrefPubMedSuche in Google Scholar
  • 22 Fernández JA, Fernández-Valiñas, Hernández D, Orozco J, Lugo A. Myasthenic crisis in an elderly patient with positive antibodies against acetylcholine and anti-MuSK, successfully treated with noninvasive mechanical ventilation. Case Reports in Critical Care 2015; 1-4
    PubMedSuche in Google Scholar
  • 23 Seneviratne J, Mandrekar J, Wijdicks EFM, Rabinstein AA. Noninvasive ventilation in myasthenic crisis. Arch Neurol 2008; 65 (1) 54-58
    CrossrefPubMedSuche in Google Scholar
  • 24 Wu JY, Kuo PH, Fan PC, Wu HD, Shih FY, Yang PC. The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis. Neurocrit Care 2009; 10 (1) 35-42
    CrossrefPubMedSuche in Google Scholar
  • 25 Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 2004; 24 (1) 75-81
    Thieme ConnectPubMedSuche in Google Scholar
  • 26 Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care 2005; 3 (3) 213-215
    CrossrefPubMedSuche in Google Scholar
  • 27 Batocchi AP, Evoli A, Di Schino C, Tonali P. Therapeutic apheresis in myasthenia gravis. Ther Apher 2000; 4 (4) 275-279
    CrossrefPubMedSuche in Google Scholar
  • 28 Yeh JH, Chen WH, Chiu HC, Bai CH. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis. J Neurol Sci 2007; 263 (1–2) 191-193
    CrossrefPubMedSuche in Google Scholar
  • 29 Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve 2013; 47 (4) 510-514
    CrossrefPubMedSuche in Google Scholar
  • 30 Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nat Rev Neurol 2015; 11 (2) 80-89
    CrossrefPubMedSuche in Google Scholar
  • 31 Gajdos P, Tranchant C, Clair B , et al; Myasthenia Gravis Clinical Study Group. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005; 62 (11) 1689-1693
    CrossrefPubMedSuche in Google Scholar
  • 32 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C ; Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41 (6) 789-796
    CrossrefPubMedSuche in Google Scholar
  • 33 Qureshi AI, Choudhry MA, Akbar MS , et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52 (3) 629-632
    CrossrefPubMedSuche in Google Scholar
  • 34 Rønager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001; 25 (12) 967-973
    CrossrefPubMedSuche in Google Scholar
  • 35 Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76 (23) 2017-2023
    CrossrefPubMedSuche in Google Scholar
  • 36 Dhawan PS, Goodman BP, Harper CM , et al. IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?: a critically appraised topic. Neurologist 2015; 19 (5) 145-148
    CrossrefPubMedSuche in Google Scholar
  • 37 Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist 2011; 1 (1) 16-22
    PubMedSuche in Google Scholar
  • 38 Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012; 12: CD002277
    PubMedSuche in Google Scholar
  • 39 Skeie GO, Apostolski S, Evoli A , et al; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17 (7) 893-902
    CrossrefPubMedSuche in Google Scholar
  • 40 Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; 4 (4) CD002275
    PubMedSuche in Google Scholar
  • 41 Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis 2011; 13 (2) 85-94
    CrossrefPubMedSuche in Google Scholar
  • 42 Amato AA, Russell JA. Disorders of neuromuscular transmission. In: Neuromuscular Disorders. 1st ed. New York: McGraw-Hill; 2008: 457-528
    Suche in Google Scholar
  • 43 Gwathmey KG, Burns TM. Myasthenia gravis. Semin Neurol 2015; 35 (4) 327-339
    Thieme ConnectPubMedSuche in Google Scholar
  • 44 Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci 1981; 377: 670-677
    CrossrefPubMedSuche in Google Scholar
  • 45 Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L ; Muscle Study Group. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. Muscle Nerve 2014; 49 (4) 483-486
    CrossrefPubMedSuche in Google Scholar
  • 46 Bansal V, Kansal MM, Rowin J. Broken heart syndrome in myasthenia gravis. Muscle Nerve 2011; 44 (6) 990-993
    CrossrefPubMedSuche in Google Scholar
  • 47 Finsterer J, Stöllberger C. Stress from myasthenic crisis triggers Takotsubo (broken heart) syndrome. Int J Cardiol 2016; 203: 616-617
    CrossrefPubMedSuche in Google Scholar
  • 48 Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366 (24) 2294-2304
    CrossrefPubMedSuche in Google Scholar
  • 49 Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255 (2) 57-65
    CrossrefPubMedSuche in Google Scholar
  • 50 Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366 (9497) 1653-1666
    CrossrefPubMedSuche in Google Scholar
  • 51 Hughes RAC, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130 (Pt 9): 2245-2257
    CrossrefPubMedSuche in Google Scholar
  • 52 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32 (2) 150-163
    CrossrefPubMedSuche in Google Scholar
  • 53 Hadden RDM, Karch H, Hartung H-P , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001; 56 (6) 758-765
    CrossrefPubMedSuche in Google Scholar
  • 54 Cao-Lormeau VM, Blake A, Mons S , et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case control study. Lancet 2016; 387: 1531-1539
    CrossrefPubMedSuche in Google Scholar
  • 55 Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 (Suppl): S21-S24
    CrossrefPubMedSuche in Google Scholar
  • 56 Brannagan III TH, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci 2003; 208 (1–2) 39-42
    CrossrefPubMedSuche in Google Scholar
  • 57 Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology 2003; 61 (4) 471-474
    CrossrefPubMedSuche in Google Scholar
  • 58 Murray NM, Wade DT. The sural sensory action potential in Guillain-Barré syndrome. Muscle Nerve 1980; 3 (5) 444
    PubMedSuche in Google Scholar
  • 59 Wijdicks EF, Borel CO. Respiratory management in acute neurologic illness. Neurology 1998; 50 (1) 11-20
    CrossrefPubMedSuche in Google Scholar
  • 60 Orlikowski D, Prigent H, Sharshar T, Lofaso F, Raphael JC. Respiratory dysfunction in Guillain-Barré syndrome. Neurocrit Care 2004; 1 (4) 415-422
    CrossrefPubMedSuche in Google Scholar
  • 61 Prigent H, Orlikowski D, Letilly N , et al. Vital capacity versus maximal inspiratory pressure in patients with Guillain-Barré syndrome and myasthenia gravis. Neurocrit Care 2012; 17 (2) 236-239
    CrossrefPubMedSuche in Google Scholar
  • 62 Walgaard C, Lingsma HF, Ruts L , et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010; 67 (6) 781-787
    CrossrefPubMedSuche in Google Scholar
  • 63 Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58 (6) 893-898
    CrossrefPubMedSuche in Google Scholar
  • 64 Kaida K, Kusunoki S, Kanzaki M, Kamakura K, Motoyoshi K, Kanazawa I. Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barré syndrome. Neurology 2004; 62 (5) 821-824
    CrossrefPubMedSuche in Google Scholar
  • 65 Sharshar T, Chevert S, Bourdain F, Raphaël JC ; French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 2003; 31 (1) 278-283
    CrossrefPubMedSuche in Google Scholar
  • 66 Durand MC, Prigent H, Sivadon-Tardy V , et al. Significance of phrenic nerve electrophysiological abnormalities in Guillain-Barré syndrome. Neurology 2005; 65 (10) 1646-1649
    CrossrefPubMedSuche in Google Scholar
  • 67 Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988; 51 (5) 605-612
    CrossrefPubMedSuche in Google Scholar
  • 68 Hughes RA, Wijdicks EF, Benson E , et al; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62 (8) 1194-1198
    CrossrefPubMedSuche in Google Scholar
  • 69 Ali MI, Fernández-Pérez ER, Pendem S, Brown DR, Wijdicks EF, Gajic O. Mechanical ventilation in patients with Guillain-Barré syndrome. Respir Care 2006; 51 (12) 1403-1407
    PubMedSuche in Google Scholar
  • 70 Nguyen TN, Badjatia N, Malhotra A, Gibbons FK, Qureshi MM, Greenberg SA. Factors predicting extubation success in patients with Guillain-Barré syndrome. Neurocrit Care 2006; 5 (3) 230-234
    CrossrefPubMedSuche in Google Scholar
  • 71 Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978; 2 (8093) 750-753
    PubMedSuche in Google Scholar
  • 72 Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341 (8845) 586-590
    PubMedSuche in Google Scholar
  • 73 The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41 (3) 298-306
    CrossrefPubMedSuche in Google Scholar
  • 74 Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126 (Pt 10): 2220-2234
    CrossrefPubMedSuche in Google Scholar
  • 75 Zhang G, Lopez PH, Li CY , et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004; 127 (Pt 5): 1085-1100
    CrossrefPubMedSuche in Google Scholar
  • 76 Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102 (3) 177-193
    CrossrefPubMedSuche in Google Scholar
  • 77 Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012; 7 (7) CD001798
    PubMedSuche in Google Scholar
  • 78 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; 9 (9) CD002063
    PubMedSuche in Google Scholar
  • 79 McKhann GM, Cornblath DR, Ho T , et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991; 338 (8767) 593-597
    CrossrefPubMedSuche in Google Scholar
  • 80 Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997; 350 (9093) 1747
    CrossrefPubMedSuche in Google Scholar
  • 81 Godoy DA, Rabinstein A. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?. Arq Neuropsiquiatr 2015; 73 (10) 848-851
    CrossrefPubMedSuche in Google Scholar
  • 82 Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994; 17 (10) 1145-1155
    CrossrefPubMedSuche in Google Scholar
  • 83 Pfeiffer G, Schiller B, Kruse J, Netzer J. Indicators of dysautonomia in severe Guillain-Barré syndrome. J Neurol 1999; 246 (11) 1015-1022
    CrossrefPubMedSuche in Google Scholar
  • 84 Chen A, Kim J, Henderson G, Berkowitz A. Posterior reversible encephalopathy syndrome in Guillain-Barré syndrome. J Clin Neurosci 2015; 22 (5) 914-916
    CrossrefPubMedSuche in Google Scholar
  • 85 Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EFM. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve 2001; 24 (7) 963-965
    CrossrefPubMedSuche in Google Scholar
  • 86 Saifudheen K, Jose J, Gafoor VA, Musthafa M. Guillain-Barre syndrome and SIADH. Neurology 2011; 76 (8) 701-704
    CrossrefPubMedSuche in Google Scholar
  • 87 Ruts L, Drenthen J, Jongen JL , et al; Dutch GBS Study Group. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology 2010; 75 (16) 1439-1447
    CrossrefPubMedSuche in Google Scholar
  • 88 Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh UK. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Anesth Analg 2005; 101 (1) 220-225
    CrossrefPubMedSuche in Google Scholar
  • 89 Pentland B, Donald SM. Pain in the Guillain-Barré syndrome: a clinical review. Pain 1994; 59 (2) 159-164
    CrossrefPubMedSuche in Google Scholar
  • 90 Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database Syst Rev 2013; 10 (10) CD009950
    PubMedSuche in Google Scholar
  • 91 The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. Brain 1996; 119 (Pt 6): 2053-2061
    CrossrefPubMedSuche in Google Scholar
  • 92 Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2012; 83 (7) 711-718
    CrossrefPubMedSuche in Google Scholar
  • 93 Koeppen S, Kraywinkel K, Wessendorf TE , et al. Long-term outcome of Guillain-Barré syndrome. Neurocrit Care 2006; 5 (3) 235-242
    CrossrefPubMedSuche in Google Scholar
  • 94 Cornblath DR, Mellits ED, Griffin JW , et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 1988; 23 (4) 354-359
    CrossrefPubMedSuche in Google Scholar
  • 95 Hiraga A, Mori M, Ogawara K , et al. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2005; 76 (5) 719-722
    CrossrefPubMedSuche in Google Scholar
  • 96 van Koningsveld R, Steyerberg EW, Hughes RAC, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007; 6 (7) 589-594
    CrossrefPubMedSuche in Google Scholar
  • 97 Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 2011; 76 (11) 968-975
    CrossrefPubMedSuche in Google Scholar
  • 98 International GBS Outcome Study (IGOS) . Available at: https://clinicaltrials.gov/ct2/show/NCT01582763 . Accessed February, 2016
    PubMed